

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Man *et al.*

Confirmation No.: 7683

Application No.: 10/685,942

Group Art Unit: 1611

Filed: October 14, 2003

Examiner: Frazier, B.

For: PHARMACEUTICALLY ACTIVE
ISOINDOLINE DERIVATIVES

Atty Docket No.: 9516-205-999
(JD 501872-999204)

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Celgene Corporation is also the assignee of the entire right, title and interest in and to the above-identified application by virtue of an assignment from Hon-Wah Man and George W. Muller to Celgene Corporation.

Celgene Corporation is the assignee of the entire right, title and interest in and to U.S. Patent No. 7,678,825 ("the '825 patent") by virtue of the same assignment because the '825 patent claims priority to this application.

Celgene Corporation hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the '825 patent, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the patent shall be commonly owned with the '825 patent.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration of the full statutory term of '825 patent in the event that the '825 patent later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of the common ownership stated above. This disclaimer is to be binding upon the grantee, its successors, or assigns.

A fee of \$ 140.00 is believed due under 37 C.F.R. 120(d) for the submission of this terminal disclaimer. Please charge this, and any other required fees, to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed.

Respectfully submitted,

Date August 24, 2000

Signed: 

By: Robert J. Hugin

Title: Chief Executive Officer